Chesapeake Capital Corp IL Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Chesapeake Capital Corp IL bought a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,051 shares of the specialty pharmaceutical company's stock, valued at approximately $376,000.

A number of other institutional investors and hedge funds have also made changes to their positions in JAZZ. Pacer Advisors Inc. grew its position in Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after purchasing an additional 115,102 shares during the last quarter. Franklin Resources Inc. grew its holdings in Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after buying an additional 48,708 shares in the last quarter. Thompson Siegel & Walmsley LLC increased its position in Jazz Pharmaceuticals by 8.3% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company's stock valued at $87,035,000 after acquiring an additional 59,685 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Jazz Pharmaceuticals by 15.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock valued at $75,801,000 after acquiring an additional 83,807 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Jazz Pharmaceuticals by 5.4% during the 4th quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock worth $58,835,000 after acquiring an additional 24,481 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded down $1.81 during trading hours on Friday, hitting $138.76. 3,643,788 shares of the company were exchanged, compared to its average volume of 703,951. The firm has a fifty day simple moving average of $131.41 and a 200-day simple moving average of $121.70. The company has a market capitalization of $8.43 billion, a PE ratio of 19.54, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares of the company's stock, valued at approximately $966,323.72. This represents a 13.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares of the company's stock, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,022,825 in the last quarter. 4.20% of the stock is owned by company insiders.

Analyst Ratings Changes

JAZZ has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Barclays reissued an "overweight" rating and set a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. HC Wainwright increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a report on Monday, March 10th. Finally, Royal Bank of Canada dropped their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.